The year in charts

You may also be interested in

Total revenues remain strong at CHF 7.2 billion (CHF 7.3 billion in 2023) Record CHF 833 million raised by privately funded companies drives 22% overall rise in capital investment to CHF 2.5 billion (CHF 2.0 billion in 2023) Alentis Therapeutics (CHF 163 million) and SixPeaks Bio (CHF 102 million) lead the way in the private financing rounds Despite market headwinds, some public companies report n
May 6, 2025

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Nagi Bioscience, a pioneering Swiss company specializing in cutting-edge laboratory technologies for alternative model organisms research, announced a strategic partnership with Rhino Bio Inc., a leading distributor for next–generation analytical systems in South Korea. The partnership accelerates Nagi Bioscience’s expansion into the South Korean market, driven by strong demand for its flagshi
May 7, 2025

Christian Moser Nikles, Patent Expert & Christel Aebischer, Patent Expert | Swiss Federal Institute of Intellectual Property
SIX Swiss Exchange reviews publicly listed companies included in ‘Highlights of 2024: Year in Review’ (Pages 52 to 55). While Santhera and Kuros made good progress, SIX recognizes the notable success of Basilea which, 20 years after its IPO in 2004, has reported increasingly robust profits.
May 5, 2025

Sirpa Tsimal, Director Investment Promotion | Switzerland Global Enterprise
Switzerland Global Enterprise’s Sirpa Tsimal talks to Leila Schwery and Michael Hübner of Johnson & Johnson about the company’s commitment to fostering global partnerships, the evolution of its manufacturing and supply chain strategies, and the critical role Switzerland plays in shaping its global capabilities.
May 5, 2025

Jan Lucht, Head Biotechnology | scienceindustries
Biotechnology applications are expanding globally into many areas beyond the pharmaceutical sector. A growing range of products meet consumer demands while contributing to sustainability and climate protection. However, the current European authorization process for these innovative products is unnecessarily burdensome and limits market access. Leading European business organizations have come tog
May 5, 2025